Comparison of fondaparinux and enoxaparin in acute coronary syndromes.

PubWeight™: 5.24‹?› | Rank: Top 1%

🔗 View Article (PMID 16537663)

Published in N Engl J Med on March 14, 2006

Authors

Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators1, Salim Yusuf, Shamir R Mehta, Susan Chrolavicius, Rizwan Afzal, Janice Pogue, Christopher B Granger, Andrzej Budaj, Ron J G Peters, Jean-Pierre Bassand, Lars Wallentin, Campbell Joyner, Keith A A Fox

Author Affiliations

1: Population Health Research Institute, McMaster Clinic, Hamilton General Hospital, 237 Barton St. East, Hamilton, ON L8L 2X2, Canada.

Associated clinical trials:

Michelangelo - Oasis 5 | NCT00139815

Articles citing this

Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation (2009) 2.93

Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Eur Heart J (2011) 2.11

Understanding equivalence and noninferiority testing. J Gen Intern Med (2010) 1.91

Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The global registry of acute coronary events. Eur Heart J (2009) 1.53

A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. Eur Heart J (2012) 1.45

Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors. BMJ (2014) 1.39

Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc (2009) 1.38

Recent advances in antithrombotic therapy after acute coronary syndrome. CMAJ (2013) 1.23

Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J (2009) 1.21

Venous thromboembolism and bleeding in a community setting. The Worcester Venous Thromboembolism Study. Thromb Haemost (2009) 1.09

Opposition: Unfractionated heparin should no longer be used in the catheterization laboratory. ASEAN Heart J (2015) 1.07

The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction. Eur Heart J (2012) 1.06

Primary PCI for acute myocardial infarction in a patient with idiopathic thrombocytopenic purpura. A case report and review of the literature. Herz (2010) 0.92

Sex-based differences in cardiac ischaemic injury and protection: therapeutic implications. Br J Pharmacol (2014) 0.91

Acute coronary syndromes without ST segment elevation. BMJ (2007) 0.88

Is platelet inhibition due to thienopyridines increased in elderly patients, in patients with previous stroke and patients with low body weight as a possible explanation of an increased bleeding risk? Neth Heart J (2011) 0.87

Comparing the predictive validity of three contemporary bleeding risk scores in acute coronary syndrome. Eur Heart J Acute Cardiovasc Care (2012) 0.87

Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients. JACC Cardiovasc Interv (2012) 0.86

Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome. Vasc Health Risk Manag (2010) 0.85

Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review. Eur Heart J (2013) 0.84

Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective. Thromb J (2011) 0.82

Management of the patient with an acute coronary syndrome using oral anticoagulation. Neth Heart J (2015) 0.82

The impact of bleeding in patients with acute coronary syndromes: how to optimize the benefits of treatment and minimize the risk. Can J Cardiol (2007) 0.81

Design and rationale of the AngioSeal versus the Radial approach In acute coronary SyndromE (ARISE) trial: a randomized comparison of a vascular closure device versus the radial approach to prevent vascular access site complications in non-ST-segment elevation acute coronary syndrome patients. Trials (2013) 0.81

[Costs caused by bleeds within the therapy of acute coronary syndromes in Germany]. Herz (2009) 0.81

Fondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies. Vasc Health Risk Manag (2010) 0.80

Contemporary treatment of unstable angina and non-ST-segment-elevation myocardial infarction (part 2). Tex Heart Inst J (2010) 0.80

Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5). BMC Cardiovasc Disord (2015) 0.79

Management of acute coronary syndromes with fondaparinux. Vasc Health Risk Manag (2007) 0.79

Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin. Vasc Health Risk Manag (2008) 0.78

Implications of bleeding in acute coronary syndrome and percutaneous coronary intervention. Vasc Health Risk Manag (2011) 0.78

Anticoagulation after anterior myocardial infarction and the risk of stroke. PLoS One (2010) 0.78

Emerging therapies for acute coronary syndromes. Front Pharmacol (2011) 0.78

The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants. Vasc Health Risk Manag (2009) 0.78

Fondaparinux versus enoxaparin in acute coronary syndromes. N Engl J Med (2006) 0.78

Anticoagulant therapy for non-ST-segment elevation acute coronary syndrome in China: A multi-center observational study. J Transl Int Med (2016) 0.77

Oral factor Xa inhibitors for the long-term management of ACS. Nat Rev Cardiol (2012) 0.77

The REG1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome. Future Cardiol (2012) 0.77

Comparison of new adenosine diphosphate receptor antagonists with clopidogrel in patients with coronary artery disease: a meta-analysis. Heart Vessels (2014) 0.77

Inhibitors of propagation of coagulation: factors V and X. Br J Clin Pharmacol (2011) 0.76

Emergency cardiac surgery in patients with acute coronary syndromes: a review of the evidence and perioperative implications of medical and mechanical therapeutics. Anesth Analg (2011) 0.76

Enoxaparin injection for the treatment of high-risk patients with non-ST elevation acute coronary syndrome. Vasc Health Risk Manag (2007) 0.76

Management of patients with unstable angina / non-ST-elevation myocardial infarction: a critical review of the 2007 ACC /AHA guidelines. Int J Clin Pract (2009) 0.76

Non ST segment elevation acute coronary syndromes: A simplified risk-orientated algorithm. Can J Cardiol (2006) 0.76

Frequency and predictors of thrombus inside the guiding catheter during interventional procedures: an optical coherence tomography study. Int J Cardiovasc Imaging (2014) 0.76

Almanac 2011: Acute Coronary Syndromes. The National Society Journals Present Selected Research that has Driven Recent Advances in Clinical Cardiology. Mater Sociomed (2011) 0.75

Antiplatelet and antithrombin strategies in acute coronary syndrome: state-of-the-art review. Curr Cardiol Rev (2012) 0.75

Potential role of rivaroxaban in patients with acute coronary syndrome. Drug Des Devel Ther (2012) 0.75

Antithrombotic agents. Fondaparinux in acute coronary syndromes: improved efficacy and safety. Rev Cardiovasc Med (2006) 0.75

Acute management of unstable angina and non-ST segment elevation myocardial infarction. Einstein (Sao Paulo) (2015) 0.75

Therapy for patients with acute coronary syndromes--new opportunities. N Engl J Med (2006) 0.75

Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data. Arq Bras Cardiol (2016) 0.75

Enoxaparin versus unfractionated heparin in ST-elevation myocardial infarction. N Engl J Med (2006) 0.75

Optimal oral antithrombotic regimes for patients with acute coronary syndrome: a network meta-analysis. PLoS One (2014) 0.75

The impact of vascular access for in-hospital major bleeding in patients with acute coronary syndrome at moderate- to very high-bleeding risk. J Korean Med Sci (2013) 0.75

OASIS-5: how do fondaparinux and enoxaparin compare in patients with acute coronary syndromes? Nat Clin Pract Cardiovasc Med (2006) 0.75

Cost Effectiveness of Antiplatelet and Antithrombotic Therapy in the Setting of Acute Coronary Syndrome: Current Perspective and Literature Review. Am J Cardiovasc Drugs (2015) 0.75

'Ins' and 'outs' of triple therapy: Optimal antiplatelet therapy in patients on chronic oral anticoagulation who need coronary stenting. Neth Heart J (2010) 0.75

Coping with new challenges in acute coronary syndromes. Can J Cardiol (2006) 0.75

Treatment dosing of low-molecular-weight heparins and the dose cap dilemma: considerations for patients in Canada. Can J Hosp Pharm (2009) 0.75

Anticoagulant therapy with fondaparinux in a liver transplant patient with thrombosis and liver fibrosis: a case report. Clin Case Rep (2017) 0.75

Fondaparinux in the management of patients with ST-elevation acute myocardial infarction. Vasc Health Risk Manag (2006) 0.75

Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention. Vasc Health Risk Manag (2009) 0.75

Thrombosis - Besieged but Poorly Understood. Front Cardiovasc Med (2014) 0.75

A Review of Current Diagnosis, Investigation, and Management of Acute Coronary Syndromes in Elderly Patients. Cardiol Ther (2015) 0.75

Arteriovenous fistula as a complication of transradial coronary angiography: a case report. J Med Case Rep (2013) 0.75

Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban. Mil Med Res (2016) 0.75

Fondaparinux was noninferior to enoxaparin for death, MI, and refractory ischemia but reduced bleeding in angina and non-STEMI. ACP J Club (2006) 0.75

Duration of dual antiplatelet therapy in acute coronary syndrome. Heart (2017) 0.75

Management of elderly patients with a non-ST-segment-elevation acute coronary syndrome. Neth Heart J (2017) 0.75

Articles by these authors

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet (2004) 42.12

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50

Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76

A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science (2007) 18.96

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25

Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34

Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet (2008) 13.15

ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J (2011) 13.10

Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J (2008) 12.31

Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 11.72

Universal definition of myocardial infarction. Circulation (2007) 11.69

Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med (2009) 11.49

ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation (2006) 11.49

Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25

Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med (2013) 11.14

Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98

Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J (2007) 9.80

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74

Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69

2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54

Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet (2004) 9.01

Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93

Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69

Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59

Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet (2011) 8.49

Third universal definition of myocardial infarction. Circulation (2012) 8.47

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12

Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 7.94

Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med (2015) 7.83

Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59

Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med (2014) 7.54

Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA (2005) 7.35

A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA (2004) 7.32

Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30

Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med (2003) 7.25

Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet (2010) 7.08

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2012) 6.94

Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet (2009) 6.83

Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81

The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet (2008) 6.72

Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA (2005) 6.68

Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med (2014) 6.65

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet (2003) 6.55

Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J (2007) 6.51

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48

Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA (2007) 6.38

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet (2010) 6.31

Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med (2009) 6.18

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med (2012) 6.16

ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol (2006) 6.11

Aspirin in patients undergoing noncardiac surgery. N Engl J Med (2014) 6.10